The Myriad myRisk® test is a 35-gene cancer panel that will provide your patients with pancreatic cancer information on:
- Whether their case of pancreatic cancer is hereditary (or caused by a genetic mutation) – 5-10% of all pancreatic cancer cases are hereditary.1
- Their risk of developing additional cancers – Having a BRCA1 or BRCA2 mutation puts pancreatic patients with cancer at a higher risk of developing other cancers than the general public.
- Potential treatment eligibility – Patients with metastatic pancreatic cancer and a BRCA mutation may be considered appropriate for PARP Inhibitor Therapy.
- Potential hereditary cancer risk for family members – Knowing mutation status provides the opportunity for family members to take proactive screening and/or preventative measures if appropriate.
By incorporating leading medical society guidelines into the results through our myRisk Medical Management Tool, myRisk can provide comprehensive information about your patient’s unique cancer. Using industry leading accuracy, unmatched turnaround time, and a lifetime commitment to patients, myRisk is an essential part of all pancreatic cancer workups.